Published in Proc Natl Acad Sci U S A on November 11, 1997
Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog (2013) 2.44
Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol (1999) 2.42
Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol (2009) 2.37
Generation of HIV latency in humanized BLT mice. J Virol (2011) 2.20
Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay. J Clin Microbiol (2001) 1.97
Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med (1999) 1.96
Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood. AIDS (2014) 1.76
Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol (1998) 1.75
Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1999) 1.68
Highly sensitive methods for quantitation of human immunodeficiency virus type 1 RNA from plasma, cells, and tissues. J Clin Microbiol (1999) 1.53
The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence. J Infect Dis (2013) 1.39
Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology (2013) 1.37
Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion. Retrovirology (2010) 1.28
Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis. Proc Natl Acad Sci U S A (1999) 1.27
Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog (2012) 1.26
Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. Retrovirology (2008) 1.21
Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy. Proc Natl Acad Sci U S A (2000) 1.20
Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. Proc Natl Acad Sci U S A (1999) 1.16
Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci (2013) 1.16
Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1999) 1.08
Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice. J Antimicrob Chemother (2010) 1.07
Rapid turnover of 2-LTR HIV-1 DNA during early stage of highly active antiretroviral therapy. PLoS One (2011) 1.04
Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection. Am J Pathol (2000) 1.03
Structured intermittent treatment for HIV disease: Necessary concession or premature compromise? Proc Natl Acad Sci U S A (2002) 0.99
Recovery and analysis of human immunodeficiency virus type 1 (HIV) RNA sequences from plasma samples with low HIV RNA levels. J Clin Microbiol (2000) 0.99
A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. HIV Seq Compend (2001) 0.98
HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites. HIV AIDS (Auckl) (2010) 0.94
Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. AIDS Res Hum Retroviruses (2015) 0.93
Level of human immunodeficiency virus DNA in peripheral blood mononuclear cells correlates with efficacy of antiretroviral therapy. J Clin Microbiol (1999) 0.91
Monitoring patients with HIV disease. J Clin Pathol (2000) 0.91
Quantitation of human immunodeficiency virus type 2 DNA in peripheral blood mononuclear cells by using a quantitative-competitive PCR assay. J Clin Microbiol (1999) 0.90
Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy. J Infect Dis (2009) 0.90
Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles. J Acquir Immune Defic Syndr (2012) 0.90
Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter. J Clin Microbiol (2002) 0.87
Proteomic analysis of HIV-infected macrophages. J Neuroimmune Pharmacol (2010) 0.85
Human T cell reconstitution in DiGeorge syndrome and HIV-1 infection. Semin Immunol (2007) 0.84
Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus function. J Clin Immunol (2005) 0.84
Influence of follicular dendritic cells on HIV dynamics. Philos Trans R Soc Lond B Biol Sci (2000) 0.84
Tissue reservoirs of HIV. Curr Opin HIV AIDS (2016) 0.83
Comparative evaluation of two branched-DNA human immunodeficiency virus type 1 RNA quantification assays with lower detection limits of 50 and 500 copies per milliliter. J Clin Microbiol (2000) 0.83
HIV-associated nephropathy in the setting of maximal virologic suppression. Pediatr Nephrol (2011) 0.82
Design and characterization of novel peptide-coated lipid nanoparticles for targeting anti-HIV drug to CD4 expressing cells. AAPS J (2012) 0.80
HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective. Curr HIV Res (2015) 0.79
Normal physiology and HIV pathophysiology of human T-cell dynamics. J Clin Invest (2000) 0.78
Viral and Cellular Dynamics in HIV Disease. Curr Infect Dis Rep (2001) 0.77
FRET-based assay to screen inhibitors of HIV-1 reverse transcriptase and nucleocapsid protein. Nucleic Acids Res (2016) 0.76
Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS. Nanomedicine (Lond) (2016) 0.75
Barriers to a cure for HIV in women. J Int AIDS Soc (2016) 0.75
Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals. Med Microbiol Immunol (2017) 0.75
HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (1993) 15.54
Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature (1993) 11.15
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science (1997) 5.55
Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother (1993) 4.96
Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science (1996) 4.72
Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis (1991) 3.16
Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol (1995) 2.85
A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity. J Clin Microbiol (1997) 1.68
The chromosomal location of T-cell receptor genes and a T cell rearranging gene: possible correlation with specific translocations in human T cell leukaemia. EMBO J (1985) 1.64
HIV-1: gambling on the evolution of drug resistance? Nat Med (1997) 1.54
Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med (1996) 1.47
Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc Natl Acad Sci U S A (1995) 0.99
Detection of HIV-1 DNA by PCR: evaluation of primer pair concordance and sensitivity of a single primer pair. J Acquir Immune Defic Syndr (1992) 0.97
Single cell transcript analysis of human immunodeficiency virus gene expression in the transition from latent to productive infection. Virology (1995) 0.95
Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma. J Infect Dis (1996) 0.90
Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes. AIDS (1997) 0.89
Viral load and immunophenotype of cells obtained from lymph nodes by fine needle aspiration as compared with peripheral blood cells in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 0.88
Random important alterations in HIV-1 viral quasispecies after antiviral treatment. Antivir Ther (1996) 0.88
Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes. J Infect Dis (1996) 0.88
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science (1989) 14.63
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 13.84
DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science (1988) 13.46
Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature (1993) 11.15
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
Changes in thymic function with age and during the treatment of HIV infection. Nature (1998) 10.27
Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell (1989) 9.66
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
Detection of viral sequences of low reiteration frequency by in situ hybridization. Proc Natl Acad Sci U S A (1978) 7.95
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66
Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol (1994) 6.76
Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol (1997) 6.61
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J Acquir Immune Defic Syndr (1989) 6.16
Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. Proc Natl Acad Sci U S A (1990) 5.85
HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med (2000) 5.79
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science (1997) 5.55
Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med (1996) 5.35
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Identification of human immunodeficiency virus sequences by using in vitro enzymatic amplification and oligomer cleavage detection. J Virol (1987) 5.27
HIV viral load markers in clinical practice. Nat Med (1996) 4.78
Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science (1996) 4.72
A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med (1992) 4.71
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
Pathogenesis of lentivirus infections. Nature (1986) 4.61
Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother (1990) 4.51
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med (1994) 4.39
The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int (2011) 4.27
Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med (1989) 4.20
Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J Virol (1994) 4.14
Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med (1997) 4.12
Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr (2000) 4.03
Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med (2001) 3.80
Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA (2001) 3.73
Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med (1996) 3.63
Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro. J Exp Med (1989) 3.63
Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis (1992) 3.61
Viral dynamics of acute HIV-1 infection. J Exp Med (1999) 3.45
Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. J Virol (1995) 3.18
Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network. IET Syst Biol (2007) 3.05
The slow infection caused by visna virus. Curr Top Microbiol Immunol (1975) 2.99
Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A (2003) 2.95
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 2.91
Enzymatic gene amplification: qualitative and quantitative methods for detecting proviral DNA amplified in vitro. J Infect Dis (1988) 2.90
Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol (1995) 2.85
Slow persistent infection caused by visna virus: role of host restriction. Science (1977) 2.83
Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA (1999) 2.82
Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. J Clin Invest (1991) 2.82
Simultaneous in situ detection of viral RNA and antigens. Proc Natl Acad Sci U S A (1984) 2.73
In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol (1997) 2.71
Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. J Clin Invest (1997) 2.69
Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol (1999) 2.68
Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis (2001) 2.63
Mixed human immunodeficiency virus (HIV) infection in an individual: demonstration of both HIV type 1 and type 2 proviral sequences by using polymerase chain reaction. J Infect Dis (1988) 2.56
A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc Natl Acad Sci U S A (1997) 2.52
Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol (1996) 2.50
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med (1990) 2.50
Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses (1998) 2.50
A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med (1990) 2.48
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther (2007) 2.48
Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J Virol (1991) 2.47
Visna DNA synthesis and the tempo of infection in vitro. Virology (1982) 2.47
Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med (1987) 2.46
Human immunodeficiency virus type 1 (HIV-1) infection a median of 18 months before a diagnostic western blot. Evidence from a cohort of homosexual men. Ann Intern Med (1989) 2.44
Nucleic acid amplification in vitro: detection of sequences with low copy numbers and application to diagnosis of human immunodeficiency virus type 1 infection. Clin Microbiol Rev (1989) 2.43
Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol (1999) 2.42
Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives. J Biol Chem (1988) 2.41
Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology (2010) 2.40
Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein. J Virol (1996) 2.40
Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci U S A (1998) 2.39
Prevalence of psychiatric disorders among men infected with human immunodeficiency virus. A controlled study. Arch Gen Psychiatry (1988) 2.36
HTLV-I-induced lymphoma mimicking Hodgkin's disease. Diagnosis by polymerase chain reaction amplification of specific HTLV-I sequences in tumor DNA. Blood (1988) 2.30
Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology (2001) 2.30
A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care (1991) 2.30
Rapid viral diagnosis. J Infect Dis (1984) 2.27
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med (1995) 2.26